As a matter of policy most pharmaceutical companies prefer to have their Myeloma patients apply to non-profit copay foundations for the financial aid money used to help pay for their drugs.
UPDATE: Financial Aid – Updated March 24, 2018
Three co-pay assistance program are now open to Myeloma patients.
• The HealthWell Foundation Multiple Myeloma Medicare Access Program is OPEN for Myeloma. The program’s maximum award level is $10,000 annually for insurance premiums, co-pay, co-insurance, and medical & prescription deductibles. The HealthWell Foundation Myeloma page can be found HERE.
• The Patient Advocate Foundation’s Co-pay Relief Fund is OPEN to Myeloma patients who earned under 400% of the 2017 Federal Poverty Level and have Medicare, Medicaid, or Military Benefits. Maximum award level is $10,000 annually for patients on a Medicare including Supplemental and Advantage plans. The PAF Co-pay Relief Fund can be found HERE.
• After briefly being fully subscribed The Leukemia & Lymphoma Society (LLS) Co-Pay Assistance Program is again OPEN for new applicants. Maximum award level is $7,500 annually to be used for Blood cancer treatment-related co-payments, Private health insurance premiums, and Medicare Part B, Medicare Plan D, Medicare Supplementary Health Insurance, Medicare Advantage premium, Medicaid Spend-down or co-pay obligations. The LLS Co-pay Relief Fund can be found HERE.
The Assistance Fund, CancerCare, Good Days/Chronic Disease Fund, and Patient Access Network Foundation (PAN) remain closed to Myeloma patients.
Please contact us if you become aware of any new programs or of any existing program re-opening. At times like this we truly need to live up to our “Support” group mission.
Even though some patient co-pay foundations have re-opened for 2018 it is still good to be aware of the drug manufactures own financial aid programs, particularly if your application is denied by a foundation.
Celgene’s (Thalomid, Revlimid, & Pamalyst) patient support web portal can be found at:
Amgen Assist 360 Program: http://www.amgenassist360.com/patient/kyprolis-cost-nurse-ambassador-assistance/
Janssen CarePath Program: https://www.darzalexhcp.com/cost-support/janssen-carepath#affordability
Bristol-Myers Squibb Empliciti (elotuzumab)
Bristol-Myers Squibb Access Support: https://www.darzalexhcp.com/cost-support/janssen-carepath#affordability
More to come (I’m sure).
2017 Health & Human Services Poverty Guidelines & Dollar Figures for 100%, Medicaid Eligibility (at 138%), 400% and 500% above the Federal Poverty Guidelines
|100%||Medicaid Eligibility (138% of FPL)||400%||500%|